Search Results 751-760 of 17396 for alopecia

1. A Study of AO-176 as Monotherapy Combinated with Bortezomib and Dexamethasone in Adults with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   Resolution of prior therapy-related AEs (including immune-related AEs but excluding alopecia) to ≤ Grade 1 (except for Grade 2 peripheral neuropathy) per CTCAE ...

2. A Study to Test Adding Pembrolizumab to Olaparib Alone as Therapy for Patients with Pancreatic Cancer That Has Spread with Inherited BRCA Mutations - Mayo Clinic

   ... alopecia. Zubrod performance status of 0-1. Patients must have a complete medical history and physical exam within 28 days prior to registration: Absolute ...

3. Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma - Mayo Clinic

   0) Grade -study baseline (except alopecia or neuropathy); Adequate organ function as defined by the following criteria: Serum aspartate transaminase (AST ...

4. Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer - Mayo Clinic

   ... alopecia; Cardiac conditions as follows: Uncontrolled hypertension (blood pressure [BP] >=150/95 mmHg despite medical therapy); Left ventricular ejection ...

5. A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer - Mayo Clinic

   o Subjects with type I diabetes mellitus, hypothyroidism requiring only hormone replacement, skin disorders (such as vitiligo,psoriasis or alopecia) not ...

6. Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas - Mayo Clinic

   ... alopecia, fatigue, and hematologic toxicities); Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to ...

7. A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies - Mayo Clinic

   0) ≤ Grade 1, or to the levels dictated in the eligibility criteria with the exception of alopecia. Patient with history of confirmed progressive ...

8. A Study to Evaluate the Effectiveness, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera - Mayo Clinic

   Clinically significant toxicity (other than alopecia) from prior therapy that has not resolved to Grade ≤ 1 (according to the NCI CTCAE, v4.0) prior to Day 1 ...

9. A Study of INCMGA00012 in Squamous Carcinoma of the Anal Canal Following Platinum-Based Chemotherapy - Mayo Clinic

   Toxicity of prior therapy that has not recovered to ≤ Grade 1 or baseline (with the exception of any grade of alopecia and anemia not requiring transfusion ...

10. Dose-Escalation Study of cevostamab (BFCR4350A) in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) - Mayo Clinic

    Any grade alopecia;; Peripheral sensory or motor neuropathy must have resolved to Grade ≤ 2. Measurable disease defined as at least one of the following ...